- |||||||||| NTX1088 / Nectin Therap
First-in-class anti-PVR mAb NTX1088 advancing through Phase I: Safe and potent in restoring DNAM1 expression to enhance antitumor immunity (Section 42) - Mar 5, 2024 - Abstract #AACR2024AACR_9202;
P1
NTX1088 is investigated as a single agent and in combination with the anti-PD1 mAb, pembrolizumab (Keytruda) in patients with advanced solid malignancies...Synergy was obtained when NTX1088 was combined with PD1 blockers, or with the anti-CD112R mAb, NTX2R13.Syngeneic models of PVRK.O, demonstrated a complete immune-mediated tumor regression...First-in-human (FIH) trial is currently ongoing and biomarker analysis is showing initial mechanistic proof of concept for NTX1088 mode of action, including the restoration of DNAM1 surface expression on patients' immune cells. This is the first case of surface DNAM1 elevation in clinical settings.
- |||||||||| NTX1088 / Nectin Therap
Phase I trial of first-in-class anti-PVR mAb NTX1088: Restoration of DNAM1 expression as MOA for enhanced antitumor immunity (Section 38; Poster Board #29) - Mar 14, 2023 - Abstract #AACR2023AACR_8233;
P1
NTX1088 will be investigated as a single agent and combined with the anti-PD1 mAb, pembrolizumab (Keytruda) in patients with locally advanced and metastatic solid malignancies.NTX1088 is a humanized, IgG4-S228P mAb that binds PVR with sub-nM affinity and blocks all known interacting receptors with a single nM EC50...Synergy was observed when NTX1088 was combined with PD1 blockers, or with the anti-CD112R mAb, NTX2R13, in line with the restoration of DNAM1 expression.Numerous humanized murine xenograft models were investigated...In conclusion, PVR blockade by NTX1088 has a remarkable pre-clinical efficacy, suggesting a potential clinical breakthrough, based on the ability of simultaneously overcome multiple tumor escape mechanisms. First-in-human (FIH) trial is currently ongoing and biomarker data is analyzed to assess clinical impact of the drug and prepare for patient stratification.
- |||||||||| NTX1088 / Nectin Therap
Enrollment open, Trial initiation date, Monotherapy, Metastases: KEYNOTE-E92: A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab (clinicaltrials.gov) - Jan 26, 2023
P1, N=90, Recruiting,
First-in-human (FIH) trial is currently ongoing and biomarker data is analyzed to assess clinical impact of the drug and prepare for patient stratification. Not yet recruiting --> Recruiting | Initiation date: Jun 2022 --> Sep 2022
- |||||||||| NTX-1088 / Nectin Therap
First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_809;
P1
Tumor-infiltrating lymphocytes, harvested from NTX1088-treated mice, demonstrated a significantly higher prevalence of CD137+, DNAM1+, CD8+ T cells compared to all other interventions. Conclusions These promising preclinical findings, together with a clean safety profile in cynomolgus monkeys, paved the way to a Ph1 clinical study in which NTX1088 is tested as a monotherapy and in combination with pembrolizumab, in patients with locally advanced and metastatic solid tumors ( NCT05378425 ).
- |||||||||| NTX-1088 / Nectin Therap
NTX-1088, a first-in-class anti-PVR mAb mediates DNAM1-dependent antitumor immunity (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7059;
Synergistic effect was obtained when NTX-1088 was combined with the anti-CD112R mAb, NTX-2R13...Furthermore, NTX-1088 in combination with pembrolizumab, was superior to the combination of pembrolizumab with tiragolumab...This is a step change in antitumor immune activation that provides a remarkable and differentiated addition to the armamentarium available to patients and their treating oncologists. An IND will be open during 2Q2022.
- |||||||||| NTX-1088 / Nectin Therap
NTX-1088, A POTENT ANTI-PVR MAB INDUCES DNAM1-MEDIATED ANTITUMOR IMMUNITY (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_882;
When compared to anti-TIGIT mAb (tiragolumab), NTX-1088 demonstrated clear superiority in activating T and NK cells as stand-alone agent...NTX-1088 shows, for the first time, exclusive triple mechanism of action, whereby simultaneous and effective blockade of TIGIT and CD96 is complemented by the efficient restoration of DNAM1. This is a step change in antitumor immune activation, which will be validated in the clinic starting early 2022.
|
